NAGE שולי רווח נקי ממכירות Chromadex Corp

Chromadex Corp leads the study of NAD+, protecting Niagen with patents, which is why the operating net margin on GURU.Markets yields the current metric 8.40. The monetization of cell rejuvenation rights through royalties ensures stability. Growth in dietary supplement contracts and new tests establish a foundation for development while the market assesses the efficiency of product implementation.
פילוחי נתונים אנליטיים מרוכזים עבור ChromaDex Corp (NAGE)

Driven by exclusive patents for Niagen and low demand elasticity within the biohacking segment, Chromadex Corp (NAGE) effectively passes inflationary costs onto consumers. By analyzing the net margin as a percentage of revenue, an investor assesses the share of final profit in every dollar of sales, which determines the speed of the business's adaptation to rising rates and confirms the stability of the issuer's capital.